Head-To-Head Comparison: Glaukos (NYSE:GKOS) and WORK Medical Technology Group (NASDAQ:WOK)

Glaukos (NYSE:GKOS) and WORK Medical Technology Group (NASDAQ:WOK) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, earnings, institutional ownership and dividends.

Risk and Volatility

Glaukos has a beta of 0.94, suggesting that its stock price is 6% less volatile than the S&P 500. Comparatively, WORK Medical Technology Group has a beta of 2.37, suggesting that its stock price is 137% more volatile than the S&P 500.

Insider & Institutional Ownership

99.0% of Glaukos shares are owned by institutional investors. 6.4% of Glaukos shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Glaukos and WORK Medical Technology Group’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Glaukos	-34.34%	-6.92%	-5.25%
WORK Medical Technology Group	N/A	N/A	N/A

Analyst Recommendations

This is a breakdown of current ratings and price targets for Glaukos and WORK Medical Technology Group, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Glaukos	1	1	11	1	2.86
WORK Medical Technology Group	1	0	0	0	1.00

Glaukos currently has a consensus target price of $144.42, suggesting a potential upside of 8.29%. Given Glaukos’ stronger consensus rating and higher possible upside, analysts clearly believe Glaukos is more favorable than WORK Medical Technology Group.

Earnings & Valuation

This table compares Glaukos and WORK Medical Technology Group”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Glaukos	$507.44 million	15.44	-$187.69 million	($3.28)	-40.66
WORK Medical Technology Group	$9.81 million	0.00	-$1.07 million	N/A	N/A

WORK Medical Technology Group has lower revenue, but higher earnings than Glaukos.

Summary

Glaukos beats WORK Medical Technology Group on 8 of the 13 factors compared between the two stocks.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.

About WORK Medical Technology Group

WORK Medical Technology Group Ltd. engages in developing health instruments. It manufactures and sells medical devices, including endotracheal tubes, laryngeal mask airways, heat and moisture exchanging filters, disposable breathing circuits, nebulizer kits, and yankauer suction sets. The company was founded on March 1, 2022 and is headquartered in Hangzhou, China.